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Abstract
Respiratory syncytial virus (RSV) infection is the leading viral cause of severe lower respiratory tract illness in young infants.
Clinical studies have documented that certain polymorphisms in the gene encoding the regulatory cytokine IL-10 are
associated with the development of severe bronchiolitis in RSV infected infants. Here, we examined the role of IL-10 in a
murine model of primary RSV infection and found that high levels of IL-10 are produced in the respiratory tract by anti-viral
effector T cells at the onset of the adaptive immune response. We demonstrated that the function of the effector T cell -
derived IL-10 in vivo is to limit the excess pulmonary inflammation and thereby to maintain critical lung function. We further
identify a novel mechanism by which effector T cell-derived IL-10 controls excess inflammation by feedback inhibition
through engagement of the IL-10 receptor on the antiviral effector T cells. Our findings suggest a potentially critical role of
effector T cell-derived IL-10 in controlling disease severity in clinical RSV infection.
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Introduction
Respiratory syncytial virus (RSV) infection is the leading viral
cause of upper and lower respiratory tract illness in young infants.
In the USA, nearly 100% of children are infected with RSV by the
age of 2–3 [1]. Approximately 1–2% of these infected children
develop moderate to severe bronchiolitis [2]. The exact mecha-
nisms underlying the development of severe pulmonary diseases in
the small proportion of children remain poorly defined. Never-
theless, in both clinical studies and animal models, severe
pulmonary disease induced by RSV infection is typically
associated with an exaggerated inflammatory response in the
lower respiratory tract, characterized by the overproduction of
pro-inflammatory cytokines/chemokines and increased infiltration
of inflammatory cells [3,4,5]. Furthermore, there is no firm
correlation between disease severity and the extent of RSV
replication [6], further suggesting a likely important role of the
host immune response to RSV in determining disease severity.
Consequently, in responding to an infectious agent like RSV with
a strong potential to induce immune-mediated pathology, there is
a need to finely balance the immuno-protective and immuno-
pathological potential of the immune response in order to insure
virus clearance without excess inflammatory injury.
IL-10 is a major regulatory cytokine with broad anti-
inflammatory properties [7]. Depending on the nature of the
pathogenic stimulus, many cell types including neutrophils, NK
cells, macrophages, dendritic cells (DC), regulatory and effector T
cells have been shown to be capable of producing IL-10 both in
vitro and in vivo in response to infection [8,9]. IL-10 is generally
viewed as a negative regulator of the response of both innate and
adaptive immune cells during infection particularly during
persistent parasitic, bacterial, and viral infections where it can
suppress pathogen clearance and/or the inflammatory response
triggered by the infectious agent [8]. Recent evidence suggests that
IL-10 may play an important regulatory role in acute viral
infections of the respiratory tract where it inhibits the development
of excess pulmonary injury in the face of normal virus clearance
from the respiratory tract [10]. These findings, along with
evidence of a link between a polymorphism in the IL-10 locus
and the severity of bronchiolitis in infants infected with RSV
[11,12,13,14], prompted us to explore the role of IL-10, and in
particular of IL-10 produced by virus-specific effector T-cells, in
controlling pulmonary injury associated with experimental murine
RSV infection.
In this study, we investigated the source and role of IL-10
during primary RSV infection. We found that high levels of this
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cytokines in the respiratory tract at the onset of the adaptive
immune response. The main cellular sources of IL-10 in the lung
are RSV-specific CD4
+ and CD8
+ effector T-cells. We show that
effector T cell-derived IL-10 during RSV infection in vivo acts to
inhibit excess inflammation in the respiratory tract and thereby
maintain critical pulmonary function in the infected host. We
further provide evidence for a novel mechanism of IL-10-mediated
inflammation where effector T cell-derived IL-10 acts in an
autocrine manner on the effector T cells to suppress excess
pulmonary inflammation induced by the anti-viral response of the
effector T cells. The implications of these findings for RSV
infection are discussed.
Results
Adaptive immune cells are the major source of IL-10
during acute RSV infection
Because of IL-109s documented role in controlling or inhibiting
the development of excess inflammation in response to infection
and injury, and due to the evidence linking expression of IL-10 to
injury severity in human RSV infection, we evaluated the role of
IL-10 in virus clearance and the control of pulmonary inflamma-
tion in a murine model of experimental RSV infection [8,14]. To
address this question, we first infected BALB/c mice with RSV
and measured by ELISA the kinetics of IL-10 release into the
bronchoalveolar lavage fluid (BALF) sampled from RSV-infected
lungs. As a measure of proinflammatory cytokine release during
infection we monitored in parallel the kinetics of IFN-c production
in the infected lungs. We found that minimal levels of either
cytokine were detected in the BALF early during infection (day 1–
3 p.i.) (Figure 1A). By day 5 p.i., a time at which RSV effector T
cells have been shown to begin infiltrating into the respiratory tract
[15], both IL-10 and IFN-c levels in the BALF increased
dramatically in a coordinated manner. The levels of the two
cytokines then decreased progressively and both returned to
background levels by day 9 p.i. (Figure 1A).
The kinetics of IL-10 and IFN-c release into the BALF and its
tight association with the influx of RSV-specific effector T cells
into lungs raised the possibility that these 2 cytokines may be
products of adaptive immune cells, or at least that their expression
is linked to the recruitment of virus-specific adaptive immune cells
into the infected lungs. To initially explore the contribution of
adaptive immune (T and/or B) cells to the IL-10 response in the
infected respiratory tract, we infected WT or Rag1
-/- mice (which
lack T and B cells) with RSV and measured IL-10 and IFN-c
levels in the BALF of these mice. We found that high levels of both
cytokines were released into the airways of WT but not Rag1
-/-
mice after RSV infection (Figure 1B). Uninfected WT (Figure 1B)
or Rag1
-/- (data not shown) mice had negligible levels of this
regulatory cytokine. These data suggest that the release of both
regulatory cytokine IL-10 and effector cytokine IFN-c following
infection is dependent on the adaptive immune T and/or B cells.
T cells are the main source of IL-10 produced in the
respiratory tract during RSV infection
To further define the cellular source(s) of IL-10 in vivo during
RSV infection, we infected the IL-10/eGFP reporter mice (Vert-
X) with RSV [16]. At day 5 p.i. (i.e at the peak of IL-10 detection
in the BALF) we harvested lung cells and measured IL-10/eGFP
expression by the liberated lung cell populations using flow
cytometry. We found that, compared to the background
fluorescence observed in lung cells from RSV infected WT mice,
a significant percentage of lung cells from infected Vert-X mice
express IL-10/eGFP (Figure 1C). More importantly we found that
IL-10/eGFP expression in the Vert-X lungs was restricted almost
exclusively (.90%) to Thy-1
+ cells infiltrating the infected lungs
and that the frequency of IL-10/eGFP
+ CD4
+ T cells among the
Thy-1
+ lymphocytes roughly equaled that of IL-10/eGFP
+ CD8
+
T cells (Figure 1C). These data further reinforced the view that
CD4
+ and CD8
+ T lymphocytes are the major cellular sources of
IL-10 in the lung during RSV infection. Next, we examined the
IL-10/eGFP expression by CD8
+ and CD4
+ T cells from the
uninfected (day 0) Vert-X lungs and from the lungs, the draining
mediastinal lymph nodes (MLN) and the spleens of RSV infected
Vert-X mice. We found that IL-10/eGFP-expressing cells are
highly enriched in the RSV infected lungs, but not in the
uninfected lungs nor in the MLN or the spleen of infected mice
(Figure 1D, E). We also investigated the kinetics of accumulation
of IL-10-expressing cells in the lungs following RSV infection and
found that the IL-10-expressing cells were restricted to the acute
phase of infection (Figure S1). Notably, even though the absolute
number of IL-10/eGFP-expressing (IL-10 mRNA
+) CD8
+ and
CD4
+ continued to increase in the lungs from d5 to d7 post
infection, the in vivo release of IL-10 protein in the airway peaks at
d5 post infection, which coincides with the fall in lung virus titers
and so the viral antigen load in the lung. This observation is
consistent with our previously reported findings [10,17] and likely
reflects dependence of IL-10 protein synthesis and release on TCR
engagement and viral antigen recognition.
IL-10 is produced in the lungs during RSV infection
primarily by effector T-cells
The coordinated release of IL-10 and IFN-c in the respiratory
tract suggests that the IL-10 producing T cells in the RSV infected
lungs may be anti-viral effector T cells capable of producing IFN-c
as well. To address this possibility, we first examined the
expression of several cell surface molecules associated with T-cell
activation and/or effector differentiation by the lung T cells from
uninfected Vert-X mice (control), along with lung IL-10/eGFP
+
and IL-10/eGFP
2 T cells from RSV infected Vert-X mice. We
found that both IL-10/eGFP
+ as well as IL-10/eGFP
2 CD8
+ T
cells from infected Vert-X lungs express high levels of T cell
activation/effector markers such as CD44, CD43, ICOS, and low
levels of naı ¨ve T cell marker CD62L suggesting that, like the
eGFP
2 CD8
+ T cells, the IL-10/eGFP
+ CD8
+ T cells likely
Author Summary
IL-10 is a major anti-inflammatory protein that plays an
essential role in regulating the balance between pathogen
clearance by the immune response and immune mediated
injury resulting from the immune response to pathogen
infection. In this report, we demonstrate that anti-viral
effector T cells, a critical cell type responsible for
respiratory syncytial virus clearance, are able to produce
a large quantity of IL-10. The function of IL-10 is to control
the immune response in order to avoid the development
of excessive pulmonary inflammation associated with the
clearance of infectious virus. We further identified a likely
mechanism that T cell-derived IL-10 operates to control
inflammation and describe a novel potential target of IL-10
action in the RSV infected lungs. Our data thus may lay the
ground for the future studies exploring the application of
IL-10 in therapeutic approaches to modulate pulmonary
inflammation and injury in young infants suffering severe
respiratory syncytial virus induced diseases.
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+ T cells (Figure 2A). Likewise,
both IL-10/eGFP
+ and IL-10/eGFP
2 CD4
+ T cells express
higher levels of those activation/effector markers compared to
control CD4
+ T cells (Figure 2A). We also FACS-sorted IL-10/
eGFP
+ and IL-10/eGFP
2 T cells from infected lungs and
measured the gene expression of signature molecules of effector
cells. We found that both CD8
+ IL-10/eGFP
+ cells and CD4
+ IL-
10/eGFP
+ cells express high levels of effector molecules such as
IFN-c, Granzyme B and the type 1 effector cell lineage specific
transcription factor T-bet [18], suggesting that the IL-10
expressing CD8
+ and CD4
+ cells are indeed type 1 effector cells
(Figure 2B, C). Consistent with this idea, we observed that all IL-
10-producing CD8
+ and most IL-10-producing CD4
+ T cells
simultaneously produce IFN-c in response to mitogenic or
antigenic stimulation in vitro in the intracellular staining assay
(ICS) (Figure 2D, E and data not shown). Furthermore, we
analyzed by ICS assay the expression of T-bet and the regulatory
T cell specific transcription factor Foxp-3 [19], in IL-10
2 IFN-c
+
(IFN-c single positive, IFN-c
SP) CD8
+ T cells, IL-10
2 IFN-c
+
(IFN-c
SP) CD4
+ T cells , IL-10
+ CD8
+ T cells and IL-10
+ CD4
+ T
cells from the infected lungs directly ex vivo. Consistent with the
mRNA levels (Figure 2B, C), we found that IL-10 positive CD8
+
or CD4
+ T cells express T-bet at levels as high as the (IL-10
2)
IFN-c single-positive CD8
+ or CD4
+ type 1 like effector cells
(Figure 2D, E). Furthermore, most of IL-10
+ CD8
+ cells and the
majority of the IL-10
+ CD4
+ T cells are Foxp-3 negative
(Figure 2F). Collectively, these data suggest that the vast majority
of the IL-10-expressing CD8
+ and CD4
+ T cells are primarily type
1 effector cells. We did however observe that a minor proportion,
up to 30%, of the IL-10
+ CD4
+ T-cells, expressed Foxp-3. These
Foxp-3
+ CD4
+ T cells were uniformly negative for IFN-c
production (Figure 2F and data not shown).
IL-10 derived from effector T cells controls host morbidity
without affecting viral clearance
To determine if the effector T cell-derived IL-10 had any
impact on the outcome of RSV infection, we examined the effect
of blockade of the IL-10 receptor (IL-10R) by in vivo administration
of a blocking anti-IL-10Ra (a-IL-10R) mAb on virus clearance,
pulmonary function and lung inflammation. We found that the
administration of a-IL-10R mAb in vivo significantly enhanced the
weight loss of RSV infected mice, particularly at day 5 and
thereafter when RSV-specific adaptive immune T cells began
infiltrating into the respiratory tract (Figure 3A). We also
determined whether three parameters of lung function, as
described in Methods, were similarly affected after blocking the
action of IL-10 in vivo. As Figure 3B demonstrates, the blockade of
IL-10 function in vivo leads to a significant decrease in lung
compliance (LC) and increase in pulmonary artery pressure (PAP)
in the treated mice at d7 post infection. In addition, although it did
Figure 1. T cells are the major source of IL-10 during Respiratory Syncyial Virus infection. (A) BALB/c mice were infected with RSV. At the
indicated days p.i., mice were sacrificed, and IL-10 and IFN-c levels in the airway were measured by ELISA. (B) WT and Rag1
-/- mice were infected with
RSV. At d5 p.i., mice were sacrificed, and IL-10 and IFN-c levels in the airway were measured by ELISA. P value was determined by unpaired two-tailed
Student t test. * indicates P,=0.05. (C–E) Vert-X mice were infected with RSV, at d5 p.i., the expression of IL-10/eGFP by lung cells was measured by
flow cytometry. (C) The phenotype of IL-10/eGFP
+ cells in the lungs was analyzed by flow cytometry. Numbers are the percentages of cells in gated
population. (D) IL-10/eGFP expression by CD8
+ and CD4
+ T cells from lungs, MLN or spleen of uninfected (Day 0) mice or d5 infected mice are
measured by flow cytometry. Numbers are the percentages of cells in gated populations. (E) The absolute numbers of IL-10/eGFP
+ CD8
+ and IL-10/
eGFP
+ CD4
+ T cells in the lungs, MLN and spleens are depicted. Data are representative of two to three independent experiments.
doi:10.1371/journal.ppat.1002173.g001
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increased in the mice treated with a-IL-10R mAb compared to the
mice administered control mAb (Figure 3B).
We next compared viral clearance in RSV infected mice which
were treated with either Rat IgG1 control mAb or a-IL-10R mAb
by plaque assay and by quantitative RT-PCR for RSV genome
copies. As Figure 3C, and D demonstrate, mice treated with a-IL-
10R mAb had cleared virus by day 7 post infection as efficiently as
the mice receiving Rat IgG1 control mAb, suggesting that the
blockade of IL-10R signaling in vivo does not alter the kinetics of
viral clearance in the lung during RSV infection. These results
collectively demonstrated that the blockade of IL-10 function in
vivo leads to enhanced host diseases without affecting viral
clearance. Although we cannot exclude formally the contribution
of IL-10 derived from the small fraction of Thy-1
2/CD3
2 IL-10
+
cells in the infected lungs (Figure 1C) to the control of
inflammation, our results strongly suggest that effector T-cells
are the major source and the most important source of this
regulatory cytokine.
To determine the role of T cell-derived IL-10 in restraining host
morbidity, we transferred naive WT or IL-10
-/- Thy1
+ cells
(including both CD4
+ and CD8
+ T cells) into Rag1
-/- mice and
infected the recipient animals with RSV. We found that Rag1
-/-
mice reconstituted with IL-10
-/- T cells had increased weight loss
compared to Rag1
-/- mice reconstituted with WT T cells following
RSV infection (Figure 3E). These data suggested that IL-10
Figure 2. IL-10 expressing T cells are mainly type 1 effector T cells. (A), Vert-X mice were infected with RSV, At d5 p.i., the expression of CD44,
CD62L, CD43 and ICOS by IL-10/eGFP
+ or IL-10/eGFP
2 T cells were measured by flow cytometry. Grey line, surface expression of the molecules
displayed by T cells isolated from naı ¨ve lungs (Control). Black line, surface expression of the molecules displayed by IL-10/eGFP
+ or IL-10/eGFP
2 T cells
isolated from d5 infected lungs. (B, C) Vert-X mice were infected with RSV, At d6 p.i., CD44
hi IL-10/eGFP
+ cells and CD44
hi IL-10/eGFP
2 T cells were
sorted from infected lungs. (B) The expression of IL-10, IFN-c, Granzyme B and T-bet genes in control (naı ¨ve) CD8
+ T-cells, CD8
+ CD44
hi IL-10/eGFP
2 T
cells and CD8
+ CD44
hi IL-10/eGFP
+ T cells was determined by quantitative RT-PCR. (C) The expression of IL-10, IFN-c, Granzyme B and T-bet genes in
control (naı ¨ve) CD4
+ T cells, CD4
+ CD44
hi IL-10/eGFP
2 T cells and CD4
+ CD44
hi IL-10/eGFP
+ T cells was determined by quantitative RT-PCR. (D. E. F.)
BALB/c mice were infected with RSV. At d5 p.i., lung cells were stimulated with PMA/Ionomycin. (D, E) The expression of IL-10, IFN-c and T-bet by
CD8
+ T cells (D) or CD4
+ T cells (E) was measured through ICS. (F) The expression of Foxp-3 by indicated cell population was measured by ICS. Data
are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1002173.g002
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response to RSV infection.
Blocking the action of IL-10 in vivo results in increased
pulmonary inflammation
We next examined whether the blockade of IL-10 action in vivo
leads to enhanced pulmonary inflammation following RSV
infection. We first determined the impact of IL-10R blockade on
the recruitment of innate inflammatory cells to the lung. We found
that IL-10R blockade resulted in a substantial increase in the
number of proinflammatory monocytic cells and notably neutro-
phils infiltrating the infected lungs (Figure 4A, B). This increase in
inflammatory monocyte and neutrophil infiltration is accompa-
nied by enhanced release of pro-inflammatory cytokines including
IL-12/23 p40, IL-6, TNF-a and IFN-c into the airways of a-IL-
10R mAb-treated mice compared to control mAb-treated mice
(Figure 4C–F). Taken together, these data suggest that a critical
function of T-cell-derived IL-10 in vivo during RSV infection is to
prevent the development of excessive pulmonary inflammation in
the infected respiratory tract associated with virus infection and
the host innate/adaptive immune response and to retain essential
lung function in the infected host without inhibiting virus
clearance.
IL-10R blockade in vivo results in enhanced
proinflammatory activity of effector T cells
Along with their role in virus clearance [20], effector T cells
have been shown to significantly contribute to lung inflammation
and host morbidity in the murine model of primary RSV infection
[3,20,21]. The enhanced morbidity, excess pulmonary inflamma-
tion/injury and altered pulmonary function observed with IL-10R
blockade during RSV infection may reflect a normal function of
IL-10 in regulating the induction, expansion and/or effector
activity of effector T cells responding in the lungs to infection. We
first investigated the impact of IL-10R blockade in vivo on the
induction (in the draining MLN) and migration of effector T cells
to the lung. Somewhat unexpectedly, the numbers of activated/
effector CD8
+ or CD4
+ T cells in the infected lungs were
comparable in mice treated either with control Rat IgG1 mAb or
a-IL-10R mAb (Figure S2). Furthermore, effector T cells from
either control or a-IL-10R-treated mice had comparable capabil-
ity to produce IFN-c and TNF-a in response to mitogenic or
antigenic stimulation (Figure 4G and data not shown), suggesting
that IL-10 does not affect the differentiation of T cells into RSV
specific effector T-cells of the Th1 or Tc1 lineage.
In view of the elevated levels of lung proinflammatory cytokines,
in particular IFN-c, we next explored the impact of IL-10R
blockade on the in vivo frequency and cytokine profile of virus-
specific T cells responding in the infected respiratory tract. For this
purpose we chose IFN-c and TNF-a as representative effector
cytokines and used the the in vivo ICS assay [22] to measure their
release by CD8
+ and CD4
+ T cells in the respiratory tract. We
found that blockade of IL-10 function in vivo triggered an increase
in the percentage/number of CD4
+ and particularly CD8
+ T cells
producing IFN-c in vivo (Figure 4H, I). In addition, the in vivo
production of TNF-a by CD8
+ T cells was also modestly increased
following IL-10R blockade during RSV infection (Figure 4H). The
Figure 3. The blockade of effector T cell-derived-IL-10 enhances host morbidity without affecting viral clearance. (A-D). BALB/c mice
were infected with RSV and then were either injected with Rat IgG1 control mAb or a-IL-10R blocking mAb. (A) Mouse weight loss was monitored
daily following infection. (B) Pulmonary function of naı ¨ve mice, Rat IgG1 mAb treated or a-IL-10R mAb treated d7 infected mice was monitored. P
value was determined by unpaired two-tailed Student t test. * indicates P,=0.05. (C) Airway virus titers from the indicated mice were determined by
plaque assay. PBS, mice were infected with RSV and received PBS. P value was determined by unpaired two-tailed Student t test. n.s.(non-significant).
(D) Lung RSV gene copies from the indicated mice were determined through quantitative RT-PCR. Flu, mice were infected with influenza A/PR8 virus.
P value was determined by unpaired two-tailed Student t test. n.s.(non-significant). (E) Either WT or IL-10
-/- naı ¨ve T cells were transferred into Rag1
-/-
mice which were then infected with RSV. Mouse weight loss was monitored daily after infection. A, B. Pooled data from three experiments are
represented. C, D, E. Pooled data from two experiments are represented.
doi:10.1371/journal.ppat.1002173.g003
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production of IFN-c on a per cell basis (Figure S3). These data
demonstrate that this effector T cell-derived IL-10 can act in vivo to
suppress the production of proinflammatory mediators by effector
T cells responding in the respiratory tract of virus infection.
Autocrine regulation of IL-10 to restrain host
inflammation and morbidity
Cells of the myeloid, monocyte/macrophage/dendritic cell
lineage are believed to be the major targets of IL-10 [7]. Therefore
IL-10 would most likely be expected to diminish the effector
activity of effector T cells in vivo by inhibiting the APC function of
these inflammatory mononuclear cells infiltrating the infected
lungs. Alternatively, the T-cell-derived IL-10 could also act in an
autocrine fashion to suppress the activation/stimulation of CD8
+
and CD4
+ lung effector T cells through the engagement of the IL-
10R on these T-cells. To explore this latter possibility, we first
isolated CD8
+ effector T cells from RSV infected lungs and
examined whether they can respond to IL-10. As Figure 5A
demonstrates, we found that CD8
+ effector T cells isolated from
infected lungs are able to respond to IL-10 treatment by
phosphorylating STAT-3. Furthermore, IL-10 is able to inhibit
the release of IFN-c by CD8
+ effector T cells in response to CD3
stimulation in the absence of antigen presenting cells (Figure 5B).
Collectively, these data demonstrated that IL-10 is able to signal to
effector T cells and suppress their proinflammatory activity. To
directly explore in vivo the possible contribution of an autocrine
mechanism of IL-10 action during RSV infection, we examined
Figure 4. The blockade of effector T cell-derived-IL-10 leads to enhanced pulmonary innate and adaptive inflammation. (A–I) BALB/c
mice were infected with RSV and treated with either Rat IgG1 control mAb or a-IL-10R blocking mAb. P value was determined by unpaired two-tailed
Student t test. * indicates P,=0.05. (A, B) At the indicated days p.i., lung inflammatory monocytes (A) and neutrophils (B) were determined by flow
cytometry. (C–F) At indicated days p.i., airway IL-6 (C), IL-12 p40 (D), TNF-a (E), IFN-c (F) were determined by ELISA. (G) At d5 p.i., lung cells were
collected and restimulated with PMA/Ionomycin. The production of IFN-c by CD4
+ and CD8
+ T cells and TNF-a by CD8
+ T cells was measured by ICS.
Numbers are the percentages of cells in gated populations. (H. I) Mice were injected with monensin to block the in vivo release of cytokine. Lung cells
were then collected and the in vivo production of IFN-c, and TNF-a determined by ICS. (H) The percentages of IFN-c
+ cells in gated lung CD8
+ or CD4
+
T cells and TNF-a
+ cells in lung CD8
+ T cells at d5 p.i. are shown. Numbers are the percentages of cells in gated populations. (I) The numbers of IFN-c
+
lung CD8
+ T cells at indicated days p.i. are shown. Data are representative of at least three independent experiments.
doi:10.1371/journal.ppat.1002173.g004
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deletion of the IL-10Ra gene selectively in CD4
+ and CD8
+ T
cells [23]. We confirmed that IL-10Ra was selectively deleted in T
cells, particularly CD8
+ T cells in the lung but not in lung
monocytes/macrophages or NK cells etc (Figure 5C and data not
shown). Notably, compared to CD8
+ effector T cells, we failed to
detect significant IL-10Ra expression in CD4
+ effector T cells
(Figure 5C). Importantly, following RSV infection, the deletion of
IL-10Ra in T cells resulted in dramatically increased release of
effector T cells derived cytokine IFN-c into the airway (Figure 5D).
Interestingly, the deletion of IL-10Ra in T cells also resulted in
significantly increased infiltration of neutrophils and monocytes
(but not T cells) into the infected lungs (Figure 5D, and Figure S4),
suggesting a role for enhanced adaptive immune-mediated
inflammation in promoting neutrophil and monocyte infiltration
to the lung. Consistent with the finding of increased inflammation
in the lung, we observed that conditional deletion of the IL-10Ra
in T cells resulted in increased weight loss and delayed recovery
following RSV infection of the knockout mice (Figure 5E).
Discussion
In this report, we examined the in vivo production, cellular
sources and function of the regulatory cytokine IL-10 during acute
pulmonary RSV infection. Importantly, the primary source of IL-
10 is the anti-viral CD4
+ and CD8
+ effector T cells recruited to the
RSV infected lungs. We demonstrate that this effector T cell-
derived IL-10 plays a critical role in preventing excess inflamma-
tion during the innate and particularly the adaptive immune
response to RSV. In the absence of IL-10 signaling, an enhanced
inflammatory response and a concomitant alteration in pulmonary
function ensues. Thus, IL-10 may play a critical role in
maintaining lung function during infection. Of note, our findings
suggest that effector T cells are not only the major source of IL-10
in the infected lungs but may also serve as important cellular
targets for the action of this regulatory cytokine, reflecting a novel
autocrine pathway for the action of IL-10 during infection.
Several lines of evidence in the current study implicate effector T
cells as the primary source of IL-10 observed in the RSV infected
respiratory tract in this model. Similar to our recently reported
findings in the murine influenza infection model [10], we noted
minimal IL-10 secretion in RSV infected Rag1
-/- mice and localized
IL-10 production by effector T cells in the infected lungs using the IL-
10 reporter Vert-X mice for infection. However, we cannot formally
exclude a major contribution of the small percentage (2%–5%) of
Thy-1
–( n e g a t i v e )cells detected to the amelioration of pathology. In this
case, however, we demonstrated that IL-10 derived solely from T-
cells are sufficient to control disease development during RSV
infection (Figure 3E) which also implicated T-cell-derived IL-10 in
the control of excess pulmonary inflammation. The IL-10-producing
effector T cells are, as we observed in this report, IL-4 and GATA-3
negative (data not shown) and thus show few features characteristic of
type 2 lineage of T cells; but rather are T-bet positive type 1 effectors.
Interestingly,weobserveda minorfraction ofT-bet
+IL-10 producers
which co-express Foxp-3, a cell population that has been recently
described in other systems [24]. Of note, CD25
+ T regulatory cells
have been recently demonstrated to modulate RSV specific CD8
+ T
cell responses and pulmonary inflammation during experimental
RSV infection [25,26,27]. How these Tregs interact with the IL-10
secreting effector T cells responding in the respiratory tract to RSV
infection to control excess inflammation will require further
investigation.
It is of interest that RSV infection induced a lower level of IL-10
release into the infected airways relative to the release of effector T
cells derived pro-inflammatory effector cytokine IFN-c than
detected in influenza infected lungs. The explanation for this
discrepancy is unclear, but this could reflect an as yet unappreciated
mechanism by which RSV infection results in an imbalance in the
expression of pro-inflammatory (e.g. IFN-c and regulatory (e.g. IL-
10) cytokines by effector T-cells resulting in exaggerated inflamma-
tion/injury profile in the infected lungs out of proportion to the
degree of RSV replication in the infected lungs.
Multiple lines of evidence both from human studies and murine
models implicate myeloid cells of the monocyte/macrophage/
dendritic cell lineage as the major targets of IL-10 action in vitro
and (in model systems) in vivo [7,9,23,28,29]. Thus results from the
current study suggest that effector T cell-derived IL-10 can act
directly on these inflammatory mononuclear cells infiltrating the
RSV infected lungs to decrease production of pro-inflammatory
cytokines/chemokines by these inflammatory mononuclear cells as
well as to modulate the expression of costimulatory ligands (e.g.
CD40, 80, 86 etc.) and T-cell stimulatory cytokines (e.g. IL-12 etc.)
[28]. The latter effects of IL-10 would be expected to diminish the
efficiency of effector T cell triggering in response to contact with
these APC populations and thus down regulating the effector
activity of T cells. While our results are consistent with such a
mechanism, our findings on the impact of conditional deletion of
the IL-10Ra selectively in T-cells suggests the novel possibility that
the effector T cell-derived IL-10 may also act in an autocrine
fashion to regulate effector T cell activity directly. Of note, using
animals deficient in IL-10Rb chain, several recent reports have
provided evidence that IL-10 may act directly on and suppress the
function of T cells including Treg cells [30] and CD4
+ T cells
directly in vivo during acute LCMV infection [31] as well as inhibit
robust memory CD8
+ T cell development [32]. It should be noted,
however, that IL-10Rb is the common subunit for receptors
recognizing several other cytokines including IL-22, IL-26 and IL-
28 etc [33]. Our results using the conditional deletion of the IL-10
receptor a chain, which is unique to IL-10, firmly establish that
effector T cells are able to respond to IL-10 directly in vivo during
infection. Furthermore, we described a novel autocirne function of
IL-10; that effector T cell-derived IL-10 is able to signal back to
effector T cells, especially CD8
+ effector T cells, to restrict the
proinflammatory cytokine production by these effector T-cells.
Importantly, this autocrine regulatory function of IL-10 acting on
effector T cells modulates pulmonary inflammation and thereby
results in diminished host morbidity. A similar autocrine
mechanism has been reported recently for regulation of IL-10
producing macrophages during endotoxin challenge [23,29]. The
mechanisms through which IL-10R engagement on activated
effector T cells acts to suppress effector T cell functions at sites of
infection are currently under investigation.
IL-10hasbeendetectedboth inrespiratorytractsecretionsand in
the serum of infants and young children during the acute phase of
RSV infection [34]. Although controversial [14,35], several lines of
evidence suggest that the level of IL-10 secretion may correlate
inversely with disease severity [12,13]. This may be particularly
evident among children hospitalized for RSV infection where those
children with symptoms of severe RSV bronchiolitis requiring
mechanical ventilation express lower levels of IL-10 than hospital-
ized children with less severe disease [13]. Similarly, a recent study
reported lowerIL-10 levels instimulated cord blood ofchildren who
were hospitalized for RSV infection before 6 months of age than in
cord blood of infected infants who were treated as outpatients [36].
Furthermore, homozygosity for certain IL-10 alleles correlates with
a higher risk of severe RSV bronchiolitis [12]. Such studies point to
the importance of IL-10 in controlling the severity of acute infection
with RSV.
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not been clearly defined. While various cell types have been
implicated as the source of this IL-10 [34,37,38,39,40], our results
point to effector T cells as a potential major source of IL-10
produced during the acute phase of RSV infection. In this
connection, we did observe a small increase of IL-10 released into
the airways (BAL fluid) prior to the dramatic increase in IL-10
production observed in the respiratory tract at the time of effector T
cell infiltration at day 5 post RSV infection. Thus, while one or
more additional cell types may contribute to the pool of IL-10
observed during acute RSV infection, our results suggest that
effectorT-cells(bothCD4
+and CD8
+)maybe amajorsource ofIL-
10 during human infection. Therefore the contribution of IL-10
from effector T cells should be rigorously evaluated in future studies
of human RSV infection. Our analysis also suggests that the RSV
specific effector T cells in the infected lungs serve as an important
target of IL-10 action. Thus, the development and extent of
immune mediated pathology in RSV infection may not only be
linked to the level of IL-10 production by effector T cells (and
potentially other cell types in the infected lungs) but also dependent
upon the effectiveness of IL-10 signaling through the IL-10R on
effector T cells leading to modulation of effector T cell function.
In summary, we have discovered a critical role of effector T cell-
derived IL-10 in controlling the pulmonary inflammation and
Figure 5. Autocrine regulation of pulmonary inflammation by effector T cell-derived IL-10 during RSV infection. (A, B). BALB/c mice
were infected with RSV. At d7 p.i., Lung CD8
+ cells were purified and stimulated as indicated in vitro. (A) CD8
+ T cells were stimulated with rIL-10 in
the absence or presence of JAK inhibitor. STAT3 phophorylation was determined by ICS. (B) CD8
+ T cells were left un-stimulated or stimulated with
plate-bound a-CD3 overnight in the absence or presence of rIL-10 or rIL-10 plus a-IL-10R. IFN-c release to the medium was determined by ELISA. (C –
F) IL-10Ra fl/fl mice or CD4-Cre
+ IL-10Ra fl/fl mice were infected with RSV. (C) The expression of IL-10Ra in lung monocytes, NK cells, CD4
+ and CD8
+ T
cells at d6 post infection was determined by flow cytometry. (D) IFN-c levels in the BALF were determined by ELISA. P value was determined by
unpaired two-tailed Student t test. * indicates P,=0.05. (E) Lung infiltrated neutrophils and inflammatory monocytes were determined by flow
cytometry. P value was determined by unpaired two-tailed Student t test. * indicates P,=0.05. (F) Mouse weight loss was monitored daily following
infection. A, B, C. Data are representative of at least two independent experiments. D, E .Pooled data from four experiments are represented. F.
Pooled data from three experiments are represented.
doi:10.1371/journal.ppat.1002173.g005
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previously unrecognized autocrine function of IL-10 in controlling
proinflammatory activity of anti-viral effector cells. Our findings
thus provide a cellular and mechanistic link to earlier clinical
studies which implicate IL-10 in the pathogenesis of RSV disease
and may provide the groundwork for future studies examining IL-
10 as a therapeutic option in the treatment of RSV induced
bronchiolitis in young infants.
Materials and Methods
Mice and infection
BALB/c mice were purchased from Taconic Farms and
Rag1-/- mice were purchased from The Jackson Laboratories.
IL-10-eGFP reporter mice (Vert-X) were obtained from C.L.
Karp from Children Hospital of Cincinnati. IL-10
-/- mice were
obtained from T. A. Wynn from NIAID, NIH. The T cell
conditional IL-10Ra knock-out mice were generated through
crossing IL-10Ra fl/fl mice to CD4-cre transgenic mice [23]. All
mice were housed in a specific pathogen-free environment and all
animal experiments were performed in accordance with protocols
approved by the University of Virginia Animal Care and Use
Committee. The A2 strain of RSV (obtained from P. L. Collins
from NIAID, NIH) was grown in HEp-2 cells (ATCC) and titered
for infectivity. We infected 10–12 week old BALB/c mice with a
dose of ,1–1.2610
7 pfu RSV in serum-free Iscove’s medium
(Invitrogen) intranasally after anesthesia with methyl ether (Matix
Scientific). For the conditional IL-10Ra mice infection (B6
background), we infected 9–12 week transgenic mice with a dose
of ,2610
7 pfu RSV in serum-free Iscove’s medium after
anesthesia with ketamine and xylazine.
Ethics statement
This study was carried out in strict accordance with the Animal
Welfare Act (Public Law 91-579) and the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health (OLAW/NIH, 2002). The protocol was
approved by the University of Virginia Animal Care and Use
Committee (ACUC, Protocol Number: 2230).
T cell transfer and infection
We purified WT or IL-10-/- Thy1 positive T cells (including
both CD4
+ and CD8
+ cells) from spleen and lymph nodes by
MACS separation. 15 million T cells were then transferred into
Rag1-/- mice i.v. 1 week after transfer, the recipient mice were
infected with RSV.
Bronchoalveolar lavage fluid (BALF) for virus and
cytokine determination
We obtained BALF by flushing the airway multiple times with a
single use of 500 ml sterile PBS through a cannula attached to a
syringe. Cells were recovered from the suspension by centrifuga-
tion at 4uC. Supernatants were collected and stored at –80uC until
use for the cytokine and virus determinations. Cytokines were
measured by ELISA (BD Biosciences) according to the manufac-
turer manuals. The viral titer in the BALF was determined
through the plaque assay in serially diluted Hep-2 cell cultures.
Quantitative reverse-transcription PCR
To measure RSV-L gene expression, we isolated RNA from the
infected lungs via Trizol (Invitrogen) and treated it with DNase I
(Invitrogen). We used random primers (Invitrogen) and Super-
script II (Invitrogen) to synthesize first-strand complementary
DNAs from equivalent amounts of RNA from each sample. We
performed real-time RT-PCR in a 7000 Real-Time PCR System
(Applied Biosystems) with SYBR Green PCR Master Mix (Applied
Biosystems). The sequence of RSV-L gene primers was previously
reported [41]. Data were generated by the comparative threshold
cycle (DCT) method by normalizing to GAPDH. For experiments
to measure host genes in effector T cells from infected Vert-X
mice. We isolated CD44
hi IL-10/eGFP
+ or CD44
hi IL-10/eGFP
-
CD8
+ T cells and CD44
hi IL-10/eGFP
+ or CD44
hi IL-10/eGFP
-
CD4
+ T cells by FACS-sorting. We then isolated RNA,
synthesized cDNA and performed real-time RT-PCR as described
above. The sequences of the primers are available upon request.
Intracellular cytokine staining (ICS)
Lung single cell suspensions were generated as described [42].
Lung cells were subsequently re-stimulated with either PMA
(100 ng/ml) and ionomycin (1 mg/ml) in the presence of Golgi-
Stop (1 ml/ml) for 5–6 h. Then cells were fixed and permeablized
using the Cyto-Fix and Perm-Wash system (BD Biosciences). Cell
surface CD4 and CD8 and intracellular IL-10 and IFN-c were
stained accordingly. Measurement of IL-10 and IFN-c producing
cells in vivo was based on a previously described protocol with
modifications [22]. Briefly, at indicated days post RSV infection
mice were injected i.v. with 500 ml of a PBS solution containing
500 mg Monensin (Sigma-Aldrich) 6 h before harvesting. Lung
single cell suspensions were prepared in the presence of monensin.
Cells were then fixed and permeablized and intracellular IL-10
and IFN-c staining was as described [43].
Interleukin-10 receptor–specific monoclonal antibody
administration in vivo
a-IL-10R blocking mAb (clone 1B1.3A) and isotype control Rat
IgG1 mAb were obtained from Schering-plough Biopharma and
Bio-express. We achieved IL-10 signaling blockade in vivo by
injecting a-IL-10R blocking mAb on day 1 (0.75 mg intraperito-
neally in 500 ml), day 3 (0.15 mg intranasally in 40 ml) and day 4
(0.75 mg intraperitoneally in 500 ml).
Measurement of pulmonary function
The functional properties of the lung i.e. the airway and
vascular mechanics are characterized by different lung function
parameters, including the pulmonary compliance, the airway
resistance and pulmonary artery pressure. The airway resistance is
an index for the resistive forces against the airflow in the airways
and depends on the diameter and length of the airways. The
airway resistance can be calculated from the relation between
transpulmonary pressure and airflow velocity. The airway
resistance increases as a consequence of narrowing of the airways
due to bronchoconstriction or obstructive processes, e.g. bronchial
edema or enhanced mucus deposition. The pulmonary compli-
ance is a marker for the functional stiffness of the lung and can be
calculated from the relation between tidal volume and transpul-
monary pressure. The pulmonary compliance decreases during
restrictive pathological processes e.g. atelectasis, fibrosis, pulmo-
nary edema or disturbed surfactant secretion. The increase in
pulmonary artery pressure is an index of vasoconstriction of lung
and represents an underlying pathophysiology resulting in
pulmonary edema or changes in pulmonary vascular resistance.
We measured the lung function using a buffer-perfused mouse
lung system (Hugo Sachs Elektronik) as previously described [44].
Briefly, at day 7 post RSV infection, mice were anesthetized with
ketamine and xylazine and ventilated with room air at 100
strokes/min with a tidal volume of 7 ml/g body weight with a
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PLoS Pathogens | www.plospathogens.org 9 August 2011 | Volume 7 | Issue 8 | e1002173positive end expiratory pressure of 2 cm H2O using the
MINIVENT mouse ventilator (Hugo Sachs Elektronik). The
pulmonary artery was cannulated via the right ventricle, and the
left ventricle was immediately tube-vented through a small incision
at the apex of the heart. The lungs were then perfused at a
constant flow of 60 ml?g body wt–1?min–1 with Krebs-Henseleit
buffer containing 2% albumin, 0.1% glucose, and 0.3% HEPES.
The perfusate buffer and isolated lungs were maintained at 37uC
throughout the experiment. Isolated lungs were allowed to
equilibrate on the apparatus during a 5-min stabilization period.
After equilibration, data were recorded for an additional 10
minutes. Hemodynamic and pulmonary parameters were contin-
uously recorded during this period by the PULMODYN data
acquisition system (Hugo Sachs Elektronik).
STAT3 staining and inhibition of cytokine release of
effector T cells
Effector T cells were purified from RSV infected lung at d7 p.i.
and resuspended in complete media. Then T cells were stimulated
with 20 ng/ml rIL-10 (eBioscience) in the presence or absence of
JAK inhibitor (JAK inhibitor I, EMD Biosciences) and 15 min
later the phosphorylation of STAT3 was determined through ICS
following previousely described protocols [10]. To measure the
inhibition of IFN-c release by IL-10, we stimulated purified T cells
(5610
5 cells/ml) with plate-bound a-CD3 (100 ml of 0.1 mg/ml a-
CD3 for 4 h at 37uC) overnight. Then the supernatant of the
culture were collected and IFN-c concentration were determined
through ELISA.
FACS analysis
All FACS antibodies are purchased from BD Biosciences or
eBioscience. The dilution of surface staining antibodies was 1 in
200 and the dilution of intracellular staining antibodies was 1 in
100. After antibody staining, we examined cells using a six-color
FACS-Canto system (BD Biosciences) and the data were analyzed
by FlowJo software (Treestar). We characterized the various cell
types according to their phenotypes as follows: neutrophils
(Ly6G
+CD11b
+Ly6c
–), monocytic cell lineage (Ly6G
–CD11-
b
+Ly6c
+), natural killer cells (NK1.1
+CD3
2), CD8
+ T lymphocytes
(Thy1
+CD8
+) and CD4
+ T lymphocytes (Thy1
+CD4
+).
Statistical analyses
Data are means 6 SEM. We used two-tailed Student’s t test for
statistical analyses. We considered all P values .0.05 not to be
significant.
Supporting Information
Figure S1 Kinetics of IL-10 expressing T cells in the
lung. Vert-X mice were infected with RSV. At indicated days p.i.,
the percentage (A) or total numbers (B, C) of IL-10/eGFP
+ CD8
+
(B) or CD4
+ (C) cells were determined by flow cytometry.
Numbers are the percentages of cells in gated populations. Data
are representative of two to three independent experiments.
(TIF)
Figure S2 IL-10R blockade in vivo does not alter the
magnitude of effector T cell infiltration to the lung. (A, B)
BALB/c mice were infected with RSV and treated either with Rat
IgG1 control mAb or a-IL-10R blocking mAb. A, B, At the
indicated days p.i., lung CD8
+ M282–90 tetramer
+ cells (A) or
CD4
+ cells were determined by flow cytometry. Data are
representative of three independent experiments.
(TIF)
Figure S3 IL-10R blockade in vivo results in increased
production of IFN-c in per cell base. BALB/c mice were
infected with RSV and treated either with Rat IgG1 control mAb
or a-IL-10R blocking mAb. Infected mice were injected with
monensin to block the in vivo release of cytokine. Then lung cells
were collected and the in vivo production of IFN-c was
determined through ICS. The mean fluorescence intensity of
IFN-c is depicted. Data are representative of three independent
experiments.
(TIF)
Figure S4 IL-10Ra deletion in T cells minimally affects
effector T cell infiltration to the lung. (A, B) IL-10Ra fl/fl
mice or CD4-Cre
+ IL-10R fl/fl mice were infected with RSV. The
numbers of total CD4
+ T cells (A) or CD8
+ (B) were determined by
flow cytometry. P value was determined by unpaired two-tailed
Student t test. n.s. non-significant. Data are representative of two
independent experiments.
(TIF)
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